Efficacy of piracetam in children with encephalitis
Phase 2
- Conditions
- Health Condition 1: G049- Encephalitis, myelitis and encephalomyelitis, unspecified
- Registration Number
- CTRI/2023/04/051722
- Lead Sponsor
- Garima Singh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with clinical diagnosis of acute encephalitis syndrome
Exclusion Criteria
Preexisting developmental delay
Parents not giving informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Functional status scale scoreTimepoint: At 0-week (baseline) and at 12-weeks
- Secondary Outcome Measures
Name Time Method Pediatric cerebral performance category scoreTimepoint: At 0-week (baseline) and at 12-weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie piracetam's neuroprotective effects in acute encephalitis syndrome (AES) in pediatric patients?
How does add-on oral piracetam compare to standard-of-care treatments for AES in terms of clinical outcomes and recovery rates?
Which biomarkers correlate with improved neurological outcomes in children receiving piracetam for AES in CTRI/2023/04/051722?
What are the potential adverse events of piracetam in 1-month-to-18-year-old AES patients and their management strategies?
Are there synergistic effects of piracetam with antiviral or immunomodulatory therapies in treating pediatric encephalitis subtypes?